This time, CausalPath results were not significant in terms of the overall network size (p = 0.2218); nevertheless, they indicate that ESR1 is significantly more active in luminal breast cancers, suggested by both its protein levels and the changes in its downstream (Figure 4C). This evidence concerns the gene ESR1 and breast cancer.